Skip to main content
. 2023 Aug 23;26(9):107705. doi: 10.1016/j.isci.2023.107705

Figure 1.

Figure 1

Screening of interferon antagonists among SARS-CoV-2 viral proteins

(A) Genome architecture of SARS-CoV-2.

(B and C) Screening of SARS-CoV-2 interferon antagonists. HEK-293T cells were co-transfected with pIFN-β-Luc together with the pRL-TK plasmids, expression plasmid for one of the indicated SARS-CoV-2 viral protein, and expression plasmid for RIG-IN (B) or MDA5 (C). At 24 h post-transfection, cells were lysed and dual luciferase activity was measured. Three independent experiments were done, and significance was calculated using Student’s two-tailed, unpaired t test. Error bars indicate SD of technical triplicates. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.